Our biopharma development services support drug discovery, protein production, cell-based assays, and preclinical screening. We deliver fast, reliable results for biotech and pharmaceutical programs.
End-to-End Solutions for Drug Discovery and Development
From gene expression and molecular biology through protein production, cell-based assays, and multi-omics analysis, Synergy Bioscience delivers integrated CRO services at every stage of your pipeline. Our multidisciplinary team covers the full spectrum of drug development activities, from early molecular biology to advanced bioanalytical characterisation.
What we offer
Molecular Biology & Genomics
Cutting-edge molecular tools to study gene expression, design constructs, and engineer biological systems with high precision and reproducibility.
Protein & Antibody Production
Scalable bioprocess solutions for the expression, production, and purification of recombinant proteins and therapeutic antibodies across multiple systems.
Protein & Antibody Characterisation
Comprehensive analytical workflows for the structural and functional characterisation of proteins, antibodies, and complex biotherapeutic molecules.
Cell-Based Assays & Cellular Engineering
Physiologically relevant in vitro assays and advanced cellular engineering strategies to model disease biology and evaluate drug candidates.
Drug Discovery & Screening
High-throughput and focused screening platforms for small molecules, antibodies, and biologics, delivering key pharmacological parameters for lead selection.
Multi-Omics & Biomarker Discovery
Integrated multi-omics approaches combining genomics, proteomics, and metabolomics data to uncover disease mechanisms and validate therapeutic biomarkers.
Molecular Biology: From Gene to Protein
Synergy Bioscience’s molecular biology platform provides the foundational tools required to study gene expression and translate genetic information into functional proteins. Our team designs and constructs custom plasmids, performs molecular cloning, and applies site-directed mutagenesis to introduce precise sequence modifications. We routinely use RT/qPCR and PCR for quantitative gene expression analysis and routinely screen all cell-based cultures via mycoplasma testing to ensure biological integrity.
- Quantitative gene expression profiling via RT/qPCR
- Custom plasmid design and vector construction
- Molecular cloning into prokaryotic and eukaryotic vectors
- Site-directed mutagenesis for structure-function studies
- Mycoplasma testing and quality assurance
Bioprocess Development for Proteins and Antibodies
Our bioprocess team delivers scalable, GMP-compatible workflows for protein expression and antibody production across bacterial, yeast, insect, and mammalian cell systems. We combine upstream bioprocess engineering with downstream protein purification strategies to produce high-quality material ready for functional and structural characterisation.
- Transient and stable protein and antibody expression
- Bioprocess scale-up and process optimisation
- Multi-step chromatographic protein purification
- Antibody production and antibody purification workflows
- Protein analysis and quality control panels
- Protein and peptide quantification by multiple methods
Labelling, Conjugation, and Advanced Biotherapeutics
We offer comprehensive protein labelling and antibody labelling services, along with the design and characterisation of antibody-drug conjugates (ADC) and antibody-oligonucleotide conjugates (AOC). Our analytical suite includes Western blotting, ELISA, and antigen-binding assays to verify conjugation efficiency and confirm functional activity post-modification.
- Fluorescent, biotin, and enzymatic protein and antibody labelling
- ADC and AOC design, synthesis, and characterisation
- Conjugation efficiency analysis and DAR determination
- Western blotting and ELISA-based antigen detection
- Peptide synthesis and characterisation
Drug Screening
Drug Screening, Cell Engineering, and Pharmacology
Our integrated drug discovery platform combines cell-based assay development with advanced cellular engineering. We support knock-down, knock-out, and over-expression models via transfection and transduction, enabling highly contextualised pharmacological studies. Key assay endpoints include cell viability, cytotoxicity, cell proliferation, and drug mechanism profiling, with dose-response parameters (IC50, EC50) reported to GLP standards.
- Small molecule and antibody screening campaigns
- Cell viability, cytotoxicity, and cell proliferation assays
- Knock-down, knock-out, and over-expression cell models
- Transfection and transduction for stable and transient models
- IC50, EC50, and safety determination for lead optimisation
- Inhibitory assays and drug mechanism elucidation
Why Synergy Bioscience
Your Trusted Development Partner
We combine deep scientific expertise with operational agility to accelerate your programme at every stage.
360° Fully Integrated Services
From gene expression and molecular cloning through protein production, drug screening, and regulatory reporting, everything under one roof.
GLP Compliance-Ready
All methods are developed and validated in accordance with ICH Q2, GLP, and applicable regulatory guidelines for IND-enabling studies.
50+ Analytical Techniques
A broad technology toolkit spanning molecular biology, bioprocess, biophysics, cell biology, multi-omics, and data science.
Fast Rapid Turnaround
Streamlined project management and dedicated scientists ensure rapid delivery without compromising scientific rigour.
360° Scientific Consulting
Expert resource reviews, data analysis, figure generation, and study reporting to support your publications and submissions.
Learn more about our pharmaceutical development services:
https://synergybioscience.com/pharmaceutical-development-services/
Stem cell research continues to advance modern medicine:
https://stemcells.nih.gov/info/basics/stc-basics